在肠促胰岛素类药物中进行选择及其重要性。 - Suppr

Suppr

超能文献

Choosing among the incretin agents and why it matters.

作者信息

Unger Jeff

机构信息

Loma Linda University School of Medicine, Loma Linda, California, USA.

出版信息

J Fam Pract. 2010 May;59(5 Suppl):S30-5.

PMID:20544056

Abstract

摘要

相似文献

Choosing among the incretin agents and why it matters.

J Fam Pract. 2010 May;59(5 Suppl):S30-5.

[The value of incretin based therapies].

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.

Distinguishing among incretin-based therapies. Introduction.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S3-4.

Incretin physiology and its role in type 2 diabetes mellitus.

J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS20-4.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245.

[Therapeutic use and adverse events of incretin-related drugs].

Nihon Rinsho. 2012 May;70 Suppl 3:699-702.

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369.

[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358.

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S5-9.

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Choosing among the incretin agents and why it matters.

J Fam Pract. 2010 May;59(5 Suppl):S30-5.

[The value of incretin based therapies].

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.

Distinguishing among incretin-based therapies. Introduction.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S3-4.

Incretin physiology and its role in type 2 diabetes mellitus.

J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS20-4.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245.

[Therapeutic use and adverse events of incretin-related drugs].

Nihon Rinsho. 2012 May;70 Suppl 3:699-702.

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369.

[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358.

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S5-9.

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20.

Choosing among the incretin agents and why it matters.

作者信息

Unger Jeff

机构信息

Loma Linda University School of Medicine, Loma Linda, California, USA.

出版信息

J Fam Pract. 2010 May;59(5 Suppl):S30-5.

PMID:20544056

Abstract

摘要